Conferences - Results from #8300

ASCO GU 2018: Analysis of an Online Tool to Explore Evolving Practice Patterns in Renal Cell Carcinoma February 12, 2018

ASCO GU 2018: Diagnostic Radiation and Testicular Germ Cell Tumor Risk February 12, 2018

ASCO GU 2018: Creation of a Tissue Expression Biomarker-augmented Prognostic Model for Patients with Metastatic Renal Cell Carcinoma February 12, 2018

ASCO GU 2018: Surgical Management of Adrenocortical Carcinoma and Adrenal Tumors February 12, 2018

ASCO GU 2018: The Future of Immuno-Oncology in Renal Cell Carcinoma February 12, 2018

ASCO GU 2018: Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: Past, Present, and Future February 12, 2018

ASCO GU 2018: Management of Marker Negative Stage IIA Testicular Cancer February 12, 2018

ASCO GU 2018: Role of Immunotherapy in Patients Undergoing Radiation Therapy for Bladder Cancer February 12, 2018

ASCO GU 2018: Serum miRNA to Predict Post-chemotherapy Viable Disease in Testicular Non-seminomatous Germ Cell Tumor Patients February 12, 2018

ASCO GU 2018: The Role of Imaging in Post-chemotherapy Masses in Germ Cell Tumors February 12, 2018

ASCO GU 2018: Phase III Trial of Adjuvant Sunitinib in Patients with High-risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis February 12, 2018

ASCO GU 2018: Safety and Efficacy of Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer February 12, 2018

ASCO GU 2018: Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium February 12, 2018

ASCO GU 2018: A Randomized Phase II Trial of Pazopanib versus Temsirolimus in Patients with Advanced Clear-cell Renal Cell Carcinoma (the TemPa trial) February 12, 2018

ASCO GU 2018: Homologous Repair Deficiency in VHL-mutated Clear Cell Renal Cell Carcinoma February 12, 2018

ASCO GU 2018: Best of Journals: Urothelial Carcinoma - Medical Oncology February 12, 2018

ASCO GU 2018: IMmotion 151: A randomized Phase III Study of Atezolizumab Plus Bevacizumab versus Sunitinib in Untreated Metastatic Renal Cell Carcinoma February 12, 2018

ASCO GU 2018: Germline Pathogenic Variants in Patients with Pheochromocytoma February 12, 2018

ASCO GU 2018: Impact of Tumor Size on Survival Outcome in mRCC Treated with Targeted Therapy February 12, 2018

ASCO GU 2018: Phase III, Randomized, Double-blind Trial of Pembrolizumab in the Adjuvant Treatment of RCC: KEYNOTE-564 February 11, 2018

Page 416 of 594